Sign In
Last checked at 
31 Oct 2025 07:00
31 October 2025
Solvonis Therapeutics plc
("Solvonis" or the "Company")
Corporate Structure Update, Disposal of Non-Core Subsidiary, and Issue of Options
Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system ("CNS") disorders, announces the completion of a series of corporate restructuring actions designed to simplify the Group's structure and align with its research and development ("R&D")-first strategy. The Company also confirms the issue of options to the Chief Executive Officer and certain Non-Executive Directors, together with the settlement of historical liabilities through the issue of equity.
Corporate Structure Update
· Irish subsidiary reorganisation.
o Awakn LS Europe Holdings Ltd has been renamed Solvonis Therapeutics Ireland Holdings Limited which now serves as the Group's intellectual property holding company; and
o Awakn Research and Development Ltd has been renamed Solvonis Therapeutics Ireland R&D Limited, one of three dedicated R&D subsidiaries.
· New R&D subsidiaries: The Company has also incorporated Solvonis Therapeutics UK R&D Ltd (United Kingdom) and Solvonis Therapeutics US R&D Inc (Delaware, United States). Together with Solvonis Therapeutics Ireland R&D Limited, these entities form a harmonised R&D framework spanning the United Kingdom, the European Union, and the United States.
· Legacy entity rationalisation: The Company has commenced the wind-down of Awakn LS Partnerships Ltd (Ireland) and 1233705 B.C. Ltd. (British Columbia, Canada) with strike-offs to follow as part of the ongoing simplification programme.
· Legacy entity disposal: The Company has sold Graft Polymer IP Limited (United Kingdom) to Meta Medix d.o.o (Slovenia) for nominal cash consideration of £1. Prior to completion, all material intellectual property relating to the Company's core activity - including the two US provisional patent applications announced on 11 July 2024, "Compositions and Methods for Treating Substance Use Disorders Using Depot Drug Delivery Systems" and "Compositions and Methods for Treating Mental Health Disorders Using Depot Drug Delivery Systems" - was transferred from Graft Polymer IP Limited to Solvonis Therapeutics Ireland Holdings Limited, where it is now held.Graft Polymer IP Limited retained only residual assets of no ongoing strategic or commercial value to the Company, and its disposal has no material financial or operational impact on Solvonis.
These actions complete the post-acquisition integration of the Group and establish a clear operating structure with consolidated IP ownership and streamlined R&D execution across the UK, Ireland, and the United States.
Issue of Equity in Lieu of Fees
The Company has also agreed with certain creditors to settle outstanding liabilities relating to services historically delivered to the Company amounting to £78,000 through the issue of 26,636,362 new ordinary shares of £0.0001 each at an issue price of £0.0033 per share. The issue includes 13,939,393 shares being allotted to Professor David Nutt, CSO, as consideration for previous services rendered. Application will be made for the new ordinary shares to be admitted to trading on the Main Market of the London Stock Exchange, with Admission expected to occur on or around Friday 7th November 2025. The new shares will rank pari passu in all respects with the existing ordinary shares. Following Admission, the Company's issued share capital will comprise 6,809,403,493 ordinary shares, each carrying one voting right.
Issue of Options to CEO
At the time of his appointment in May 2024, it was agreed that Chief Executive Officer Anthony Tennyson would become eligible for the award of options subject to the successful completion of certain milestones contributing to the strategic transformation of Solvonis. All such milestones have since been achieved; however, due to successive closed periods since his appointment, the formal issuance of these options has only now been completed. Accordingly, 180,000,000 share options have been granted to Mr Tennyson, exercisable over ordinary shares of £0.001 each at an exercise price of £0.001 per share.
Issue of Options to PDMR's
Non-executive directors Nicholas Nelson and Dr Renata Crome have each been granted 21 million share options under the Company's existing long term incentive plan ("LTIP"), exercisable over ordinary shares of £0.001 each in Solvonis Therapeutics Plc at an exercise price of £0.0034 & £0.00163 respectively per share. The options have a three-year life and vest in three equal tranches: one-third on grant date, one-third on the first anniversary of grant date, and one-third on the second anniversary of grant.
Admission and Total Voting Rights
Application will be made for the New Ordinary Shares to be admitted to trading on the Main Market of the London Stock Exchange and to listing in the FCA's Official List Equity Shares (transition) category ("Admission"). It is expected that Admission will become effective at 8.00 a.m. on or around Friday 7th November 2025.
Following Admission, the Company's issued ordinary share capital will comprise 6,809,403,493 ordinary shares of £0.001 each. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Enquiries:Solvonis Therapeutics plcAnthony Tennyson, CEO & Executive Directoranthony@solvonis.comSinger Capital Markets (Broker)Phil Davies+44 (0) 20 7496 3000
About Solvonis Therapeutics plc
Solvonis Therapeutics plc (LSE: SVNS) is an emerging biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous system (CNS) disorders. Headquartered in London and listed on the main market of the London Stock Exchange, Solvonis is advancing a differentiated pipeline of repurposed and novel compounds across addiction, psychiatry, and neurology.
The Company's lead programmes address Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD), with additional discovery work supporting expansion into broader CNS indications. Its lead asset, SVN-001, is currently in Phase 3 for severe AUD in the UK, while SVN-002 is preparing for a Phase 2b trial in the US targeting moderate-to-severe AUD. The preclinical PTSD programme (SVN-SDN-14) leverages novel serotonin-dopamine modulators designed to enhance pro-social behaviour and long-term outcomes.
In parallel, Solvonis is advancing proprietary CNS discovery programmes built on a dedicated compound library to identify new small-molecule modulators of key neurotransmitter systems. This platform enables efficient early-stage innovation and supports the Company's integrated approach to developing therapies across its three strategic pillars.
With a capital-efficient model, dual development strategy, and near-term partnering opportunities, Solvonis is positioned to deliver sustained value through innovation in CNS therapeutics.
solvonis.com | LinkedIn | X (Twitter)
Director/PDMR MAR disclosures
The following notification, made in accordance with the requirements of the UK Market Abuse Regulation, gives further details.
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||||||||||
a) | Name |
| ||||||||||||
2 | Reason for the notification | |||||||||||||
a) | Position/status | See above
| ||||||||||||
b) | Initial notification /Amendment | Initial notification | ||||||||||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||
a) | Name | Solvonis Therapeutics Plc | ||||||||||||
b) | LEI | 2138005PH7OJRCRPUD88 | ||||||||||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||||||
a)
| Description of the financial instrument, type of instrument Identification code | Ordinary shares of £0.001 each in Solvonis Therapeutics Plc
Identification code (ISIN) for Solvonis Therapeutics Plc ordinary shares: GB00BMD1Z199 | ||||||||||||
b) | Nature of the transaction | 1. Issue of unapproved Share Options 2. Issue of Long Term Incentive Plan ('LTIPs') 3. Issue of Long Term Incentive Plan ('LTIPs') | ||||||||||||
c) | Price(s) and volume(s) |
| ||||||||||||
d) | Aggregated information: - Aggregated volume - Price | N/A | ||||||||||||
e) | Date of the transaction | 30 October 2025 | ||||||||||||
f) | Place of the transaction | London Stock Exchange, XLON | ||||||||||||
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name |
Prof. David Nutt
| ||||
2 | Reason for the notification | |||||
a) | Position/status | Chief Scientific Officer | ||||
b) | Initial notification /Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Solvonis Therapeutics Plc | ||||
b) | LEI | 2138005PH7OJRCRPUD88 | ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a)
| Description of the financial instrument, type of instrument Identification code | Ordinary shares of £0.001 each in Solvonis Therapeutics Plc
Identification code (ISIN) for Solvonis Therapeutics Plc ordinary shares: GB00BMD1Z199 | ||||
b) | Nature of the transaction | Issue of Ordinary Shares | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information: - Aggregated volume - Price | N/A | ||||
e) | Date of the transaction | 30 October 2025 | ||||
f) | Place of the transaction | London Stock Exchange, XLON | ||||
Follow the stocks
